miR-155 Expression in Episodic and Chronic Migraine
Unknown statusNCT05891808
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Migraine is a common, yet often disabling, neurological disease that affects over 1 billion people around the world. It's the second most disabling disease globally and the leading cause of disability for people under the age of 50, especially women. The effects of migraine aren't limited to the individual, with a tremendous economic impact on families, friends, and employers. To help reduce this burden, research is now focusing on developing biomarkers that can help with diagnosis, predicting response to treatments, and identifying those at risk of developing chronic migraine. MicroRNAs (miRNAs) are one of the most promising classes, as they can modulate gene expression and affect a wide range of cellular processes. Other studies have already observed different miRNA expression in those with episodic migraine or chronic migraine, but no specific miRNAs have been identified as a strong and specific migraine signature. miRNA-155 is of particular interest, as it has been linked to inflammation and pain, and may be a potential target for migraine treatments. It is known that the immune system plays a role in migraine headaches. Monocytes, a type of immune cell, may be involved in the development of migraines. Certain medicines, such as aspirin, can affect monocyte function and have been used to treat migraines. Recent research has also shown that microRNAs can regulate the activity of these cells and influence inflammation, which may be linked to migraine attacks. This study aims to investigate the role of miRNA-155 and monocyte differentiation in migraine patients, and in particular its association with migraine phenotype and severity. We aim to study three groups of subjects: Episodic migraine (EM), Chronic migraine with or without Medication Overuse Headache (CM-MOH) and Healthy Controls (HCs).
Study details
- Official title
- Expression of miR-155 in Migraine: Association With Different Phenotypes and Disease Severity
- Conditions
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
- Start date
- 2020-09-22
- Primary completion
- 2024-01-01
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Italy
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Healthy Controls: Inclusion Criteria: 1\. age between \>18 and \<65 years, of both genders Exclusion criteria: 1. diagnosis of primary and/or secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension type headache is allowed) 2. diagnosis of neurological disorders 3. diagnosis of medical conditions considered clinically relevant by the researcher 4. pregnant and lactating women 5. taking NSAIDs, triptans or opiates in the previous 24 hours Episodic Migraine Inclusion Criteria: 1. diagnosis of migraine without or with aura according to ICHD-III criteria 2. age between \>18 and \<65 years of both genders 3. have completed a headache diary for at least 3 months at the time of enrollment Exclusion criteria: 1. history of chronic migraine or other chronic headache subtypes according to ICHD-III criteria 2. concomitant diagnosis of other primary and/or secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension headache is allowed) 3. diagnosis of other neurological disorders 4. diagnosis of medical conditions considered clinically relevant by the researcher 5. diagnosis of chronic pain syndrome of any nature 6. pregnant and lactating women 7. use of substances of abuse 8. taking NSAIDs, triptans or opiates in the previous 24 hours Chronic Migraine Inclusion Criteria: 1. diagnosis of chronic migraine with or without concomitant diagnosis of medication overuse headache according to ICHD-III criteria 2. history of chronic migraine for at least 1 year 3. age between \>18 and \<65 years, of both sexes 4. have completed a headache diary for at least 3 months at the time of enrollment Exclusion criteria: 1. concomitant diagnosis of other primary and/or secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension headache is allowed) 2. concomitant diagnosis of other neurological disorders 3. diagnosis of medical conditions considered clinically relevant by the researcher 4. diagnosis of chronic pain syndrome of any nature 5. pregnant and lactating women 6. use of substances of abuse 7. taking NSAIDs, triptans or opiates within the previous 24 hours
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05891808